Latest Industry Insights

Technology Networks spoke with Dr Roman Fischer to learn more about the challenges researchers face in the field of clinical proteomics, and how 4D proteomics workflows are enhancing his laboratory's work.

Digitization is a trend threading many disciplines, and lateral flow is no exception. Here, we share insights from Dave Taylor, co-founder and chief operating officer of Bond Digital Health, a UK-based life sciences company that develops app and cloud technology solutions for lateral flow diagnostics.

We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.

Fluid Imaging Technologies and the University of Colorado Boulder have recently entered an exclusive research agreement to determine whether the University’s artificial intelligence software can identify bloodborne bacteria. We spoke with Kent Peterson, CEO, Fluid Imaging Technologies, to learn more about the collaboration, the technologies involved, and how they could impact patients.

We recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.

Microscopy is a key tool in many areas of research, but what happens when what you want to study is in a remote location, doesn’t transport well or you need instant answers? Well, then the analysis has to go to the sample. We spoke to Andrew Monk, cofounder of ioLight, about ioLight’s conception and what makes it so special.

In this interview, Aaron Hudson, Vice President & General Manager, Global Marketing & Strategy at SCIEX, discusses why precision quantification, specifically quantitative mass spectrometry (MS), is the best approach for measuring the transition from "wellness" to illness.

Earlier in 2019, Waters Corporation announced their BioAccord LC-MS System for biopharmaceutical analysis. We spoke with John Gebler, PhD, Director of Strategic Business Development at Waters Corporation to learn more about the BioAccord System and its applications.

Pupillometry is an ingenious way of assessing brain health by measuring data from patients’ eyes. New technology has helped standardize pupillometry, and these measurements are now helping treat patients with life-threatening brain injuries. We spoke to Kathleen Pierson, Vice President, Global Sales and Marketing, at pupillometry leader NeurOptics, to find out more.

The Zika virus poses a significant global risk, and there is currently no vaccine or specific treatment available for those infected. Having access to sensitive and specific diagnostic assays is essential to disease management, and in enabling effective research and the development of therapeutics. We spoke to Nick Roesen, Founder and COO of The Native Antigen Company, to learn about the Zika virus immunoassays that have been developed to overcome cross-reactivity with Dengue.